Brucellosis Vaccines Market Size to Worth USD 389.50 Mn by 2033

The global brucellosis vaccines market size is expected to increase USD 389.50 million by 2033 from USD 242.70 million in 2023 with a CAGR of 4.84% between 2024 and 2033.

Key Points

  • The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
  • North America has dominated the market with revenue share of 43% in 2023.
  • By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
  • By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
  • By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
  • By distribution channel, the public segment had the largest market share in 2023.

Brucellosis Vaccines Market Size 2024 to 2033

The Brucellosis Vaccines Market focuses on vaccines designed to prevent brucellosis, a zoonotic infection primarily affecting livestock but also transmissible to humans. The market includes vaccines for both animals and humans, with a strong focus on controlling the disease in livestock populations to prevent human infections. Brucellosis can cause severe health issues, including reproductive problems in livestock and flu-like symptoms in humans. Vaccination is an essential component of disease control strategies worldwide.

Get a Sample: https://www.precedenceresearch.com/sample/4113

Growth Factors:

The growth of the brucellosis vaccines market is driven by several factors, including the rising awareness of zoonotic diseases and their impact on human health. Increasing demand for safe and high-quality livestock products also encourages the adoption of vaccination programs to ensure the health of animals. Additionally, government initiatives and regulations mandating disease control measures contribute to market growth. Advances in vaccine development, such as new formulations and delivery methods, further fuel market expansion.

Region Insights:

The brucellosis vaccines market varies across regions due to differences in disease prevalence, livestock populations, and regulatory environments. In regions where brucellosis is endemic, such as parts of Africa, Asia, and Latin America, the demand for vaccines is high. North America and Europe have well-established vaccination programs and strict regulations for controlling the disease. Emerging markets in Asia-Pacific and Latin America offer significant growth potential due to increasing livestock populations and rising awareness of disease prevention.

Brucellosis Vaccines Market Scope

Report Coverage Details
Global Market Size in 2023 USD 242.70 Million
Global Market Size in 2024 USD 254.46 Million
Global Market Size by 2033 USD 389.50 Million
Growth Rate from 2024 to 2033 CAGR of 4.84%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type, By Vaccine, By Application, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Brucellosis Vaccines Market Dynamics

Drivers:

Key drivers of the brucellosis vaccines market include the need to control the spread of the disease, which can cause significant economic losses in the livestock industry. Public health concerns related to zoonotic transmission also play a role in driving market demand. Additionally, technological advancements in vaccine production, such as improved formulations and delivery systems, contribute to the market’s growth. Government support and funding for vaccination programs further enhance market development.

Opportunities:

Opportunities in the brucellosis vaccines market include the development of more effective and long-lasting vaccines for both animals and humans. The use of novel technologies, such as mRNA and DNA-based vaccines, presents potential for innovation in the field. Expansion into emerging markets with high disease prevalence offers growth prospects, as does collaboration between governments, research institutions, and vaccine manufacturers to improve disease control measures.

Challenges:

Challenges in the brucellosis vaccines market include the complexity of the disease and the need for efficient and safe vaccines that can provide long-term protection. Ensuring vaccine accessibility and affordability in low-resource settings is another hurdle. Additionally, vaccine hesitancy and resistance to vaccination programs in some regions can hinder market growth. Regulatory and logistical challenges related to vaccine production and distribution also pose obstacles to market expansion.

Read Also: Dental Caries Treatment Market Size to Cross USD 11.60 Bn by 2033

Brucellosis Vaccines Market Recent Developments

  • In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
  • In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
  • In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
  • In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.

Brucellosis Vaccines Market Companies

  • Merck & Co.
  • CZ Vaccines
  • Colorado Serum Company
  • Indian Immunologicals
  • Hester Biosciences
  • Veterinary Technologies Corporation
  • Laboratorios Tornel
  • Five Animal Health
  • VETAL Animal Health Products Inc.

Segments Covered in the Report

By Type

  • Rbs1 Vaccine
  • S19 Vaccine
  • Others

By Vaccine

  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine

By Application

  • Cattle
  • Sheep & Goat
  • Others

By Distribution Channel

  • Veterinary Hospitals & Clinics
  • Retail Channels
  • Public

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Leave a Reply

Your email address will not be published. Required fields are marked *